AR126603A1 - Composiciones y métodos para anticuerpos anti-pacap - Google Patents
Composiciones y métodos para anticuerpos anti-pacapInfo
- Publication number
- AR126603A1 AR126603A1 ARP220102018A ARP220102018A AR126603A1 AR 126603 A1 AR126603 A1 AR 126603A1 AR P220102018 A ARP220102018 A AR P220102018A AR P220102018 A ARP220102018 A AR P220102018A AR 126603 A1 AR126603 A1 AR 126603A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- antibody
- nos
- cdr1
- cdr2
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 208000019695 Migraine disease Diseases 0.000 abstract 6
- 206010027599 migraine Diseases 0.000 abstract 6
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 abstract 3
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 208000006561 Cluster Headache Diseases 0.000 abstract 2
- 206010019233 Headaches Diseases 0.000 abstract 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 2
- 235000004279 alanine Nutrition 0.000 abstract 2
- 235000001014 amino acid Nutrition 0.000 abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 208000018912 cluster headache syndrome Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 231100000869 headache Toxicity 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 2
- 238000006467 substitution reaction Methods 0.000 abstract 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 abstract 1
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 abstract 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 abstract 1
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 abstract 1
- 241001303601 Rosacea Species 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 201000004700 rosacea Diseases 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Reivindicación 1: Un anticuerpo antipolipéptido activador de la adenilato ciclasa hipofisiaria (PACAP), donde dicho anticuerpo comprende secuencias de la región variable de cadena pesada (VH)-CDR1, VH-CDR2 y VH-CDR3 establecidas en las SEQ ID Nº 9, 2 y 3, respectivamente; y una secuencia de región variable de cadena ligera (VL)-CDR1, VL-CDR2 y VL-CDR3 establecida en las SEQ ID Nº 10, 5 y 6, respectivamente. Reivindicación 2: Un anticuerpo anti-PACAP, donde dicho anticuerpo o fragmento de unión al antígeno de este comprende secuencias VH-CDR1, VH-CDR2 y VH-CDR3 seleccionadas del grupo que consiste en lo siguiente: a) SEQ ID Nº 1, 2 y 3; respectivamente. b) SEQ ID Nº 7, 2 y 3, respectivamente; y c) una variante de a) a b) que comprende 1, 2 o 3 sustituciones conservadoras de aminoácidos; y donde dicho anticuerpo o fragmento de unión al antígeno de este comprende secuencias VL-CDR1, VL-CDR2 y VL-CDR3 seleccionadas del grupo que consiste en lo siguiente: d) SEQ ID Nº 4, 5 y 6; respectivamente. e) SEQ ID Nº 8, 5 y 6; respectivamente; y f) una variante de d) a e) que comprende 1, 2 o 3 sustituciones conservadoras de aminoácidos Reivindicación 3: Un anticuerpo anti-PACAP, donde dicho anticuerpo comprende una secuencia VH derivada de la SEQ ID Nº 19, donde dicha secuencia VH comprende una valina (V) o leucina (L) en el residuo 32 según la numeración de Kabat; y donde dicho anticuerpo comprende una secuencia VL derivada de la SEQ ID Nº 22, donde dicha secuencia VL comprende alanina (A) en el residuo 27E, según la numeración de Kabat, y un triptofano (W) y una alanina (A) en los residuos 50 y 51, respectivamente, según la numeración de Kabat. Reivindicación 9: Un anticuerpo anti-PACAP, donde dicho anticuerpo comprende secuencias VH-CDR1, VH-CDR2 y VH-CDR3, y secuencias VL-CDR1, VL-CDR2 y VL-CDR3 seleccionadas del grupo que consiste en lo siguiente: a) SEQ ID Nº 1, 2 y 3, y las SEQ ID Nº 4, 5 y 6, respectivamente b) SEQ ID Nº 7, 2 y 3, y las SEQ ID Nº 8, 5 y 6, respectivamente c) SEQ ID Nº 1, 2 y 3, y las SEQ ID Nº 8, 5 y 6, respectivamente; y d) SEQ ID Nº 7, 2 y 3, y las SEQ ID Nº 4, 5 y 6, respectivamente Reivindicación 42: Un método para tratar o prevenir una afección en un individuo, que comprende administrar al individuo una cantidad terapéuticamente eficaz del anticuerpo o de la composición farmacéutica de una cualquiera de las reivindicaciones anteriores, donde la afección se selecciona del grupo que consiste en: dolor de cabeza (p. ej., migraña, cefalea en racimos, migraña refractaria), ansiedad, depresión, PTSD, afecciones comórbidas (p. ej., ansiedad / depresión / PTSD) con cefalea (p. ej., migraña, cefalea en racimos, migraña refractaria), trastornos de ansiedad comórbidos con migraña, síndrome de dolor regional complejo y rosácea. Reivindicación 52: Un método para tratar o prevenir la migraña en un individuo que no responde a anticuerpos monoclonales de la vía CGRP, que comprende administrar al individuo una cantidad terapéuticamente eficaz del anticuerpo o de la composición farmacéutica de una cualquiera de las reivindicaciones anteriores.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163226875P | 2021-07-29 | 2021-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126603A1 true AR126603A1 (es) | 2023-10-25 |
Family
ID=85088265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102018A AR126603A1 (es) | 2021-07-29 | 2022-07-28 | Composiciones y métodos para anticuerpos anti-pacap |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12358980B2 (es) |
| EP (1) | EP4377343A4 (es) |
| JP (1) | JP2024527029A (es) |
| KR (1) | KR20240046192A (es) |
| CN (1) | CN118556079A (es) |
| AR (1) | AR126603A1 (es) |
| AU (1) | AU2022317808A1 (es) |
| CA (1) | CA3227549A1 (es) |
| CL (1) | CL2024000248A1 (es) |
| CO (1) | CO2024000763A2 (es) |
| IL (1) | IL310329A (es) |
| MX (1) | MX2024001304A (es) |
| PE (1) | PE20240809A1 (es) |
| TW (1) | TW202317643A (es) |
| WO (1) | WO2023010065A2 (es) |
| ZA (1) | ZA202401405B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3227549A1 (en) | 2021-07-29 | 2023-02-02 | Cephalon Llc | Compositions and methods for anti-pacap antibodies |
| CN120958024A (zh) * | 2023-02-01 | 2025-11-14 | 瑟法隆有限责任公司 | 抗PACAP IgG4抗体的组合物和方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0522159B1 (en) | 1990-03-17 | 2001-12-12 | Takeda Chemical Industries, Ltd. | Antibody to pituitary adenylate cyclase activating peptide-pacap, hybridoma and assay for pacap |
| WO2004062684A2 (en) | 2003-01-16 | 2004-07-29 | D. Collen Research Foundation Vzw Onderwijs En Navorsing Campus Gasthuisberg K.U. Leuven | Treatment of thrombocytopenia with inhibitors of pacap |
| JPWO2008018472A1 (ja) | 2006-08-08 | 2009-12-24 | 国立大学法人京都大学 | 新規モノクローナル抗体およびその用途 |
| JP2012508017A (ja) | 2008-11-07 | 2012-04-05 | ファブラス エルエルシー | 抗ｄｌｌ４抗体及びその使用 |
| US9939449B2 (en) | 2011-02-01 | 2018-04-10 | The University Of Vermont And State Agricultural College | Diagnostic and therapeutic methods and products related to anxiety disorders |
| US9394368B2 (en) | 2013-02-20 | 2016-07-19 | Novartis Ag | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor |
| US9676851B2 (en) | 2013-03-15 | 2017-06-13 | Amgen Inc. | Human PAC1 antibodies |
| MX2017003247A (es) | 2014-09-15 | 2017-11-30 | Amgen Inc | Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas. |
| MX2017013113A (es) | 2015-04-16 | 2018-07-06 | Alder Biopharmaceuticals Inc | Anticuerpos anti-pacap y sus usos. |
| MA43567A (fr) * | 2015-12-15 | 2018-11-14 | Amgen Inc | Anticorps pacap et leurs utilisations |
| SG10202109689QA (en) * | 2016-04-15 | 2021-10-28 | Alder Biopharmaceuticals Inc | Humanized anti-pacap antibodies and uses thereof |
| WO2018152687A1 (en) * | 2017-02-22 | 2018-08-30 | I-Mab | Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof |
| AR113022A1 (es) * | 2017-09-29 | 2020-01-15 | Lilly Co Eli | Anticuerpo anti-pacap |
| CA3087951A1 (en) | 2018-01-12 | 2019-07-18 | Amgen Inc. | Pac1 antibodies and uses thereof |
| WO2020264384A1 (en) | 2019-06-28 | 2020-12-30 | Amgen Inc. | Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins |
| CA3227549A1 (en) | 2021-07-29 | 2023-02-02 | Cephalon Llc | Compositions and methods for anti-pacap antibodies |
| IL322653A (en) | 2023-02-14 | 2025-10-01 | H Lundbeck As | Treating pain caused by opioids |
| WO2024218541A1 (en) | 2023-04-20 | 2024-10-24 | Mark Hasleton | Treatment of migraine |
-
2022
- 2022-07-28 CA CA3227549A patent/CA3227549A1/en active Pending
- 2022-07-28 TW TW111128326A patent/TW202317643A/zh unknown
- 2022-07-28 EP EP22850508.7A patent/EP4377343A4/en active Pending
- 2022-07-28 IL IL310329A patent/IL310329A/en unknown
- 2022-07-28 KR KR1020247006427A patent/KR20240046192A/ko active Pending
- 2022-07-28 MX MX2024001304A patent/MX2024001304A/es unknown
- 2022-07-28 CN CN202280063638.2A patent/CN118556079A/zh active Pending
- 2022-07-28 PE PE2024000157A patent/PE20240809A1/es unknown
- 2022-07-28 US US17/815,749 patent/US12358980B2/en active Active
- 2022-07-28 AU AU2022317808A patent/AU2022317808A1/en active Pending
- 2022-07-28 WO PCT/US2022/074238 patent/WO2023010065A2/en not_active Ceased
- 2022-07-28 JP JP2024504838A patent/JP2024527029A/ja active Pending
- 2022-07-28 AR ARP220102018A patent/AR126603A1/es unknown
-
2024
- 2024-01-26 CL CL2024000248A patent/CL2024000248A1/es unknown
- 2024-01-26 CO CONC2024/0000763A patent/CO2024000763A2/es unknown
- 2024-02-15 ZA ZA2024/01405A patent/ZA202401405B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3227549A1 (en) | 2023-02-02 |
| TW202317643A (zh) | 2023-05-01 |
| EP4377343A4 (en) | 2025-06-18 |
| WO2023010065A3 (en) | 2023-03-16 |
| ZA202401405B (en) | 2025-06-25 |
| US20230212281A1 (en) | 2023-07-06 |
| CN118556079A (zh) | 2024-08-27 |
| KR20240046192A (ko) | 2024-04-08 |
| MX2024001304A (es) | 2024-05-23 |
| WO2023010065A2 (en) | 2023-02-02 |
| US12358980B2 (en) | 2025-07-15 |
| PE20240809A1 (es) | 2024-04-18 |
| EP4377343A2 (en) | 2024-06-05 |
| JP2024527029A (ja) | 2024-07-19 |
| AU2022317808A1 (en) | 2024-02-08 |
| CO2024000763A2 (es) | 2024-04-18 |
| CL2024000248A1 (es) | 2024-08-30 |
| IL310329A (en) | 2024-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11932682B2 (en) | Neutralizing anti-influenza A antibodies and uses thereof | |
| AR126603A1 (es) | Composiciones y métodos para anticuerpos anti-pacap | |
| JP7525980B2 (ja) | 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法 | |
| JP2025024066A (ja) | 抗アクチビンａ抗体及びその使用 | |
| KR101920521B1 (ko) | 중화 프로락틴 수용체 항체 Mat3 및 그의 치료 용도 | |
| JP2020063268A (ja) | 抗ｔｒｅｍ２抗体及びその使用方法 | |
| CO6150192A2 (es) | Anticuerpos monoclonales anti-il-6 y usos de los mismos | |
| CN116063499A (zh) | 抗cd33抗体及其使用方法 | |
| JP2014523745A (ja) | 抗ｃｘｃｒ４抗体及び使用方法 | |
| HRP20160082T1 (hr) | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka | |
| JP2021074013A (ja) | 抗ｂ型インフルエンザ抗体の中和及びその使用 | |
| PE20231105A1 (es) | Moleculas de union a antigeno multi-especificas contra el vih y metodos de uso | |
| AR105978A1 (es) | Moléculas de unión a linfopoyetina estromal tímica (tslp) y métodos de uso de las moléculas | |
| EA202092458A1 (ru) | Композиции на основе рекомбинантного слитого белка, содержащего нейрегулин-1 (nrg-1) человека, и способы их применения | |
| CN114072423A (zh) | 涉及抗cd39抗体和抗pd-1或抗pd-l1抗体的组合疗法 | |
| TW202108621A (zh) | 抗-sema3a抗體及其用於治療眼或眼部疾病之用途 | |
| KR20140068877A (ko) | 불응성 종양에서의 혈관신생의 억제 | |
| WO2022153212A1 (en) | Antibodies neutralizing sars-cov-2 | |
| HK40057425A (en) | Neutralizing anti-influenza b antibodies and uses thereof | |
| AR124721A1 (es) | Anticuerpos contra la calicreína plasmática y usos de estos | |
| AR129565A1 (es) | Anticuerpos igf1r |